TAB-PROFEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TAB-PROFEN (TAB-PROFEN).
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
| Metabolism | Hepatic via CYP2C9; minor pathways include glucuronidation and CYP3A4. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%). |
| Half-life | The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment. |
| Protein binding | Approximately 99% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.2 L/kg, indicating limited extravascular distribution and primarily restricted to the central compartment. |
| Bioavailability | Oral: 85-95% (rapidly absorbed with first-pass metabolism <10%); rectal: 70-80%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-15 minutes; intramuscular: 15-30 minutes. |
| Duration of Action | Oral: 4-6 hours; intravenous/intramuscular: 4-6 hours. Analgesic effect may persist longer (up to 8 hours) with higher doses. |
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: reduce dose by 50% and increase interval to every 8-12 hours; eGFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use. |
| Pediatric use | 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day. |
| Geriatric use | Initiate at lowest effective dose (e.g., 200-400 mg every 8-12 hours); maximum 2000 mg/day; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TAB-PROFEN (TAB-PROFEN).
| Breastfeeding | Compatible with breastfeeding. M/P ratio 1.2. Low infant dose (<1% maternal weight-adjusted dose). Monitor infant for rash, drowsiness, or gastrointestinal effects. |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: Increased risk of cardiac defects (OR 1.3-3.4) and gastroschisis (OR 2.4). Second/third trimester: Premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage. Avoid after 30 weeks. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal; increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines.
| Serious Effects |
Hypersensitivity to ibuprofen or any component; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; active peptic ulcer disease or GI bleeding.
| Precautions | Cardiovascular risk (especially in patients with established CVD or risk factors); GI bleeding and ulceration; renal toxicity; hypertension; fluid retention; anaphylactoid reactions; serious skin reactions (e.g., Stevens-Johnson syndrome); avoid in late pregnancy. |
Loading safety data…
| Monitor fetal heart rate, amniotic fluid index (weekly after 32 weeks if used >48h), ductus arteriosus Doppler if prolonged use. Maternal: renal function, liver enzymes, CBC, signs of bleeding. |
| Fertility Effects | Reversible inhibition of prostaglandin synthesis may impair implantation and ovulation. Use may delay time to conception. Discontinue if pregnancy is planned. |